ERYTHROMYCIN - erythromycin tablet, film coated

United States - English - NLM (National Library of Medicine)

Buy It Now

Active ingredient:
ERYTHROMYCIN (UNII: 63937KV33D) (ERYTHROMYCIN - UNII:63937KV33D)
Available from:
STAT RX USA LLC
INN (International Name):
ERYTHROMYCIN
Composition:
ERYTHROMYCIN 250 mg
Administration route:
ORAL
Prescription type:
PRESCRIPTION DRUG
Therapeutic indications:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Erythromycin Base Filmtab tablets and other antibacterial drugs, Erythromycin Base Filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin Base Filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the ery
Product summary:
Erythromycin Base Filmtab tablets (erythromycin tablets, USP) are supplied as pink, unscored oval tablets in the following strengths and packages. 250 mg tablets (debossed with Abbott “A” logo and EB): Bottles of 100…...…………………………………………………..(NDC 0074-6326-13); Bottles of 500……………………………………………………….(NDC 0074-6326-53); ABBO-PAC® unit dose strip packages of 100 tablets……………...(NDC 0074-6326-11). 500 mg tablets (debossed with Abbott “A” logo and EA): Bottles of 100……………………………………………………….(NDC 0074-6227-13). Store below 86°F (30°C). Keep tightly closed.
Authorization status:
Abbreviated New Drug Application
Authorization number:
16590-091-30, 16590-091-60, 16590-091-90

ERYTHROMYCIN - erythromycin tablet, film coated

STAT RX USA LLC

----------

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Erythromycin

Base Filmtab tablets and other antibacterial drugs, Erythromycin Base Filmtab tablets would be used

only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Erythromycin Base Filmtab (erythromycin tablets, USP) is an antibacterial product containing

erythromycin, USP, in a unique, nonenteric film coating for oral administration. Erythromycin Base

Filmtab tablets are available in two strengths containing either 250 mg or 500 mg of erythromycin base.

Erythromycin is produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus )

and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids.

Erythromycin is a white to off-white powder, slightly soluble in water, and soluble in alcohol,

chloroform, and ether. Erythromycin is known chemically as (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*,

12R*, 13S*, 14R*)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-

7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-

hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. The molecular formula is C

H NO , and the

molecular weight is 733.94. The structural formula is:

Inactive Ingredients

Colloidal silicon dioxide, croscarmellose sodium, crospovidone, D and C Red No. 30 Aluminum Lake,

hydroxypropyl cellulose, hypromellose, hydroxypropyl methylcellulose phthalate, magnesium stearate,

microcrystalline cellulose, povidone, polyethylene glycol, propylene glycol, sodium citrate, sodium

hydroxide, sorbic acid, sorbitan monooleate, talc, and titanium dioxide.

CLINICAL PHARMACOLOGY

Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active

form. Interindividual variations in the absorption of erythromycin are, however, observed, and some

patients do not achieve optimal serum levels. Erythromycin is largely bound to plasma proteins. After

absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal

inflammation, low concentrations are normally achieved in the spinal fluid but the passage of the drug

across the blood-brain barrier increases in meningitis. Erythromycin crosses the placental barrier, but

fetal plasma levels are low. The drug is excreted in human milk. Erythromycin is not removed by

peritoneal dialysis or hemodialysis.

In the presence of normal hepatic function, erythromycin is concentrated in the liver and is excreted in

the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. After oral

administration, less than 5% of the administered dose can be recovered in the active form in the urine.

Optimal blood levels are obtained when Erythromycin Base Filmtab tablets are given in the fasting state

(at least ½ hour and preferably 2 hours before meals). Bioavailability data are available from Abbott

Laboratories, Dept. 42W.

Microbiology

Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible

organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated in vitro between

erythromycin and clindamycin, lincomycin, and chloramphenicol.

Many strains of Haemophilus influenzae are resistant to erythromycin alone but are susceptible to

erythromycin and sulfonamides used concomitantly.

Staphylococci resistant to erythromycin may emerge during a course of erythromycin therapy.

Erythromycin has been shown to be active against most strains of the following microorganisms, both in

vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Gram-positive organisms

Corynebacterium diphtheriae

Corynebacterium minutissimum

Listeria monocytogenes

Staphylococcus aureus (resistant organisms may emerge during treatment)

Streptococcus pneumoniae

Streptococcus pyogenes

Gram-negative organisms

Bordetella pertussis

Legionella pneumophila

Neisseria gonorrhoeae

Other microorganisms

Chlamydia trachomatis

Entamoeba histolytica

Mycoplasma pneumoniae

Treponema pallidum

Ureaplasma urealyticum

The following in vitro data are available, but their clinical significance is unknown.

Erythromycin exhibits in vitro minimal inhibitory concentrations (MIC's) of 0.5 µg/mL or less against

most (≥ 90%) strains of the following microorganisms; however, the safety and effectiveness of

erythromycin in treating clinical infections due to these microorganisms have not been established in

adequate and well-controlled clinical trials.

Gram-positive organisms

Viridans group streptococci

Gram-negative organisms

Moraxella catarrhalis

Susceptibility Tests

Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MIC's).

These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC's

should be determined using a standardized procedure. Standardized procedures are based on a dilution

method (broth or agar) or equivalent with standardized inoculum concentrations and standardized

concentrations of erythromycin powder. The MIC values should be interpreted according to the

following criteria:

MIC (µg/mL)

Interpretation

≤ 0.5

Susceptible (S)

Intermediate (I)

≥ 8

Resistant (R)

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial

compound in the blood reaches the concentrations usually achievable. A report of "Intermediate"

indicates that the result should be considered equivocal, and, if the microorganism is not fully

susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies

possible clinical applicability in body sites where the drug is physiologically concentrated or in

situations where high dosage of drug can be used. This category also provides a buffer zone which

prevents small uncontrolled technical factors from causing major discrepancies in interpretation.

A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial

compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control microorganisms to

control the technical aspects of the laboratory procedures. Standard erythromycin powder should

provide the following MIC values:

Microorganis m

MIC (µg/mL)

S. aureus ATCC 29213

0.12-0.5

E. faecalis ATCC 29212

Diffusion Techniques

Quantitative methods that require measurement of zone diameters also provide reproducible estimates

of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure

requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated

with 15-µg erythromycin to test the susceptibility of microorganisms to erythromycin.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15-

µg erythromycin disk should be interpreted according to the following criteria:

Zone Diameter (mm)

Interpretation

≥ 23

Susceptible (S)

14-22

Intermediate (I)

≤ 13

Resistant (R)

Interpretation should be as stated above for results using dilution techniques. Interpretation involves

correlation of the diameter obtained in the disk test with the MIC for erythromycin.

As with standardized dilution techniques, diffusion methods require the use of laboratory control

microorganisms that are used to control the technical aspects of the laboratory procedures. For the

diffusion technique, the 15-µg erythromycin disk should provide the following zone diameters in these

laboratory test quality control strains:

Microorganis m

Zone Diameter (mm)

S. aureus ATCC 25923

22-30

INDICATIONS AND USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Erythromycin

Base Filmtab tablets and other antibacterial drugs, Erythromycin Base Filmtab tablets should be used

only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible

bacteria. When culture and susceptibility information are available, they should be considered in

selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and

susceptibility patterns may contribute to the empiric selection of therapy.

Erythromycin Base Filmtab tablets are indicated in the treatment of infections caused by susceptible

strains of the designated microorganisms in the diseases listed below:

Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes;

Streptococcus pneumoniae; Haemophilus influenzae (when used concomitantly with adequate doses of

sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations

ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.)

Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or

Streptococcus pneumoniae.

Listeriosis caused by Listeria monocytogenes.

Respiratory tract infections due to Mycoplasma pneumoniae.

Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or

Staphylococcus aureus (resistant staphylococci may emerge during treatment).

Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the

organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical

studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible

individuals.

Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent

establishment of carriers and to eradicate the organism in carriers.

Erythrasma - In the treatment of infections due to Corynebacterium minutissimum.

Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis

requires treatment with other agents.

Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: Erythrocin Lactobionate-I.V.

(erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative

drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with

a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving

erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.

Erythromycins are indicated for treatment of the following infections caused by Chlamydia trachomatis:

conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When

tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of

uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.

When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of

nongonococcal urethritis caused by Ureaplasma urealyticum.

Primary syphilis caused by Treponema pallidum. Erythromycin (oral forms only) is an alternative choice

of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis,

spinal fluid should be examined before treatment and as part of the follow-up after therapy.

Legionnaires' Disease caused by Legionella pneumophila. Although no controlled clinical efficacy

studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may

be effective in treating Legionnaires' Disease.

Prophylaxis

Prevention of Initial Attacks of Rheumatic Fever

Penicillin is considered by the American Heart Association to be the drug of choice in the prevention

of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper

respiratory tract e.g., tonsillitis, or pharyngitis).

Erythromycin is indicated for the treatment of

penicillin-allergic patients. The therapeutic dose should be administered for ten days.

Prevention of Recurrent Attacks of Rheumatic Fever

Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice

in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and

sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term

prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).

CONTRAINDICATIONS

Erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic.

Erythromycin is contraindicated in patients taking terfenadine, astemizole, pimozide, or cisapride. (See

PRECAUTIONS - Drug Interactions .)

WARNINGS

There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular

and/or cholestatic hepatitis, with or without jaundice, occurring in patients receiving oral erythromycin

products.

There have been reports suggesting that erythromycin does not reach the fetus in adequate

concentration to prevent congenital syphilis. Infants born to women treated during pregnancy with oral

erythromycin for early syphilis should be treated with an appropriate penicillin regimen.

Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving

erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and

erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels.

(See package insert for lovastatin.)

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including

erythromycin, and may range in severity from mild to life threatening. Therefore, it is important

to consider this diagnosis in patients who present with diarrhea subsequent to the administration

of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of

clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibiotic-

associated colitis".

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be

initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone.

In moderate to severe cases, consideration should be given to management with fluids and electrolytes,

protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridium

difficile colitis.

PRECAUTIONS

General

Prescribing Erythromycin Base Filmtab tablets in the absence of a proven or strongly suspected

bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases

the risk of the development of drug-resistant bacteria.

Since erythromycin is principally excreted by the liver, caution should be exercised when erythromycin

is administered to patients with impaired hepatic function. (See CLINICAL PHARMACOLOGY and

WARNINGS.)

There have been reports that erythromycin may aggravate the weakness of patients with myasthenia

gravis.

There have been reports of infantile hypertrophic pyloric stenosis (IHPS) occurring in infants

following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for

pertussis prophylaxis, seven neonates (5%) developed symptoms of non-bilious vomiting or irritability

with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. A

possible dose-response effect was described with an absolute risk of IHPS of 5.1% for infants who

took erythromycin for 8-14 days and 10% for infants who took erythromycin for 15-21 days.

Since

erythromycin may be used in the treatment of conditions in infants which are associated with significant

mortality or morbidity (such as pertussis or neonatal Chlamydia trachomatis infections), the benefit of

erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should

be informed to contact their physician if vomiting or irritability with feeding occurs.

Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible bacteria or

fungi. If superinfection occurs, erythromycin should be discontinued and appropriate therapy instituted.

When indicated, incision and drainage or other surgical procedures should be performed in conjunction

with antibiotic therapy.

Information for Patients

Patients should be counseled that antibacterial drugs including Erythromycin Base Filmtab tablets

should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common

cold). When Erythromycin Base Filmtab tablets is prescribed to treat a bacterial infection, patients

should be told that although it is common to feel better early in the course of therapy, the medication

should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1)

decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will

develop resistance and will not be treatable by Erythromycin Base Filmtab tablets or other antibacterial

drugs in the future.

Drug Interactions

Erythromycin use in patients who are receiving high doses of theophylline may be associated with an

increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline

toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while

the patient is receiving concomitant erythromycin therapy.

Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin

serum levels.

There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants

were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with

oral anticoagulants may be more pronounced in the elderly.

Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme

system (CYP3A). Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be

associated with elevations in drug concentrations that could increase or prolong both the therapeutic

and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible,

serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients

concurrently receiving erythromycin.

The following are examples of some clinically significant CYP3A based drug interactions. Interactions

with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based

drug interactions have been observed with erythromycin products in post-marketing experience:

Ergotamine/dihydroergotamine

Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some

patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

Triazolobenzodiazepines (Such as Triazolam and Alprazolam) and Related Benzodiazepines

Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may

increase the pharmacologic effect of these benzodiazepines.

HMG-CoA Reductase Inhibitors

Erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g.,

lovastatin and simvastatin). Rare reports of rhabdomyolysis have been reported in patients taking these

drugs concomitantly.

Sildenafil (Viagra)

Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. Reduction of

sildenafil dosage should be considered. (See Viagra package insert.)

There have been spontaneous or published reports of CYP3A based interactions of erythromycin with

cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine,

methylprednisolone, cilostazol, vinblastine, and bromocriptine.

Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is

contraindicated. (See CONTRAINDICATIONS.)

In addition, there have been reports of interactions of erythromycin with drugs not thought to be

metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.

Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines

terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse

events, including electrocardiographic QT/QT interval prolongation, cardiac arrest, torsades de

pointes, and other ventricular arrhythmias, have been observed. (See CONTRAINDICATIONS.) In

addition, deaths have been reported rarely with concomitant administration of terfenadine and

erythromycin.

There have been post-marketing reports of drug interactions when erythromycin was co-administered

with cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular

fibrillation, and torsades de pointes, most likely due to the inhibition of hepatic metabolism of cisapride

by erythromycin. Fatalities have been reported. (See CONTRAINDICATIONS).

Drug/Laboratory Test Interactions

Erythromycin interferes with the fluorometric determination of urinary catecholamines.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term (2-year) oral studies conducted in rats with erythromycin base did not provide evidence of

tumorigenicity. Mutagenicity studies have not been conducted. There was no apparent effect on male or

female fertility in rats fed erythromycin (base) at levels up to 0.25 percent of diet.

Pregnancy

Teratogenic effects

Pregnancy Category B

There is no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed

erythromycin base (up to 0.25 percent of diet) prior to and during mating, during gestation, and through

weaning of two successive litters. There are, however, no adequate and well-controlled studies in

pregnant women. Because animal reproduction studies are not always predictive of human response, this

drug should be used during pregnancy only if clearly needed.

Labor and Delivery

The effect of erythromycin on labor and delivery is unknown.

Nursing Mothers

Erythromycin is excreted in human milk. Caution should be exercised when erythromycin is

administered to a nursing woman.

Pediatric Use

See INDICATIONS AND USAGEand DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-

related. They include nausea, vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis,

hepatic dysfunction and/or abnormal liver function test results may occur. (See WARNINGS.)

Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See

WARNINGS.)

Erythromycin has been associated with QT prolongation and ventricular arrhythmias, including

ventricular tachycardia and torsades de pointes.

Allergic reactions ranging from urticaria to anaphylaxis have occurred. Skin reactions ranging from

mild eruptions to erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have

been reported rarely.

There have been rare reports of pancreatitis and convulsions.

There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal

insufficiency and in patients receiving high doses of erythromycin.

OVERDOSAGE

In case of overdosage, erythromycin should be discontinued. Overdosage should be handled with the

prompt elimination of unabsorbed drug and all other appropriate measures should be instituted.

Erythromycin is not removed by peritoneal dialysis or hemodialysis.

DOSAGE AND ADMINISTRATION

Optimal blood levels are obtained when Erythromycin Base Filmtab tablets are given in the fasting state

(at least ½ hour and preferably 2 hours before meals).

Adults

The usual dosage of Erythromycin Base Filmtab is one 250 mg tablet four times daily in equally spaced

doses or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the

severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g

daily are administered.

Children

Age, weight, and severity of the infection are important factors in determining the proper dosage. The

usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe infections this dosage

may be doubled but should not exceed 4 g per day.

In the treatment of streptococcal infections of the upper respiratory tract (e.g., tonsillitis or pharyngitis),

the therapeutic dosage of erythromycin should be administered for at least ten days.

The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in

long-term prophylaxis of streptococcal upper respiratory tract infections for the prevention of

recurring attacks of rheumatic fever in patients allergic to penicillin and sulfonamides.

Conjunctivitis of the Newborn Caused by Chlamydia trachomatis

Oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks.

Pneumonia of Infancy Caused by Chlamydia trachomatis

Although the optimal duration of therapy has not been established, the recommended therapy is oral

erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.

Urogenital Infections During Pregnancy Due to Chlamydia trachomatis

Although the optimal dose and duration of therapy have not been established, the suggested treatment is

500 mg of erythromycin by mouth four times a day on an empty stomach for at least 7 days. For women

who cannot tolerate this regimen, a decreased dose of one erythromycin 500 mg tablet orally every 12

hours or 250 mg by mouth four times a day should be used for at least 14 days.

For adults with uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia

trachomatis, when tetracycline is contraindicated or not tolerated

500 mg of erythromycin by mouth four times a day for at least 7 days.

For patients with nongonococcal urethritis caused by Ureaplasma urealyticum when tetracycline is

contraindicated or not tolerated

500 mg of erythromycin by mouth four times a day for at least seven days.

Primary Syphilis

30 to 40 g given in divided doses over a period of 10 to 15 days.

Acute Pelvic Inflammatory Disease Caused by N. gonorrhoeae

500 mg Erythrocin® Lactobionate-I.V. (erythromycin lactobionate for injection, USP) every 6 hours

for 3 days, followed by 500 mg of erythromycin base orally every 12 hours for 7 days.

Intestinal AmebiasisAdults

500 mg every 12 hours or 250 mg every 6 hours for 10 to 14 days.

Children

30 to 50 mg/kg/day in divided doses for 10 to 14 days.

Pertus s is

Although optimal dosage and duration have not been established, doses of erythromycin utilized in

reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.

Legionnaires' Disease

Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g

daily in divided doses.

HOW SUPPLIED

Erythromycin Base Filmtab tablets (erythromycin tablets, USP) are supplied as pink, unscored oval

tablets in the following strengths and packages.

250 mg tablets (debossed with Abbott “A” logo and EB):

Bottles of 100…...…………………………………………………..(NDC 0074-6326-13);

Bottles of 500……………………………………………………….(NDC 0074-6326-53);

ABBO-PAC unit dose strip packages of 100 tablets……………...(NDC 0074-6326-11).

500 mg tablets (debossed with Abbott “A” logo and EA):

Bottles of 100……………………………………………………….(NDC 0074-6227-13).

Recommended Storage

Store below 86°F (30°C). Keep tightly closed.

REFERENCES

1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial

Susceptibility Tests for Bacteria that Grow Aerobically, Third Edition. Approved Standard NCCLS

Document M7-A3, Vol. 13, No. 25 NCCLS, Villanova , PA, December 1993.

2. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disk

Susceptibility Tests, Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24

NCCLS, Villanova , PA, December 1993.

3. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on

Cardiovascular Disease in the Young, the American Heart Association: Prevention of Rheumatic

Fever. Circulation. 78(4):1082-1086, October 1988.

4. Honein, M.A., et. al.: Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with

erythromycin: a case review and cohort study. The Lancet 1999;354 (9196):2101-5.

5. Data on file, Abbott Laboratories.

FILMTAB—Film-sealed tablets, Abbott.

Abbott Laboratories

North Chicago, IL 60064, U.S.A.

PACKAGE LABEL - ERYTHROMYCIN 250 MG TABS

ERYTHROMYCIN

erythromycin tablet, film coated

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:16 59 0 -0 9 1(NDC:0 0 74-6 326 )

Route of Administration

ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

ERYTHRO MYCIN (UNII: 6 39 37KV33D) (ERYTHROMYCIN - UNII:6 39 37KV33D)

ERYTHROMYCIN

250 mg

Inactive Ingredients

Ingredient Name

Stre ng th

CO LLO IDAL SILICO N DIO XIDE (UNII: ETJ7Z6 XBU4)

CRO SCARMELLO SE SO DIUM (UNII: M28 OL1HH48 )

CRO SPO VIDO NE (UNII: 6 8 40 19 6 0 MK)

HYDRO XYPRO PYL CELLULO SE (UNII: RFW2ET6 71P)

HYPRO MELLO SES (UNII: 3NXW29 V3WO)

MAGNESIUM STEARATE (UNII: 70 0 9 7M6 I30 )

CELLULO SE, MICRO CRYSTALLINE (UNII: OP1R32D6 1U)

PO VIDO NE (UNII: FZ9 8 9 GH9 4E)

PO LYETHYLENE GLYCO L (UNII: 3WJQ0 SDW1A)

PRO PYLENE GLYCO L (UNII: 6 DC9 Q16 7V3)

SO DIUM CITRATE (UNII: 1Q73Q2JULR)

SO DIUM HYDRO XIDE (UNII: 55X0 4QC32I)

SO RBIC ACID (UNII: X0 45WJ9 8 9 B)

SO RBITAN MO NO O LEATE (UNII: 0 6 XEA2VD56 )

TITANIUM DIO XIDE (UNII: 15FIX9 V2JP)

Product Characteristics

Color

pink

S core

2 pieces

S hap e

OVAL

S iz e

15mm

Flavor

Imprint Code

Contains

Packag ing

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:16 59 0 -0 9 1-30

30 in 1 BOTTLE

2

NDC:16 59 0 -0 9 1-6 0

6 0 in 1 BOTTLE

3

NDC:16 59 0 -0 9 1-9 0

9 0 in 1 BOTTLE

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 6 16 21

0 7/11/19 72

STAT RX USA LLC

Labeler -

ST AT RX USA LLC (786036330)

Establishment

Name

Ad d re s s

ID/FEI

Busine ss Ope rations

STAT RX USA LLC

78 6 0 36 330

re la be l

Revised: 3/2011

Similar products

Search alerts related to this product

Share this information